Kaken Pharmaceutical : Presentation material for meeting

Consolidated Financial Results

for the Second Quarter of FY2022

(Six Months ended September 30, 2022)

November 9, 2022

KAKEN PHARMACEUTICAL CO., LTD.

Notes:

• The performance forecasts described herein are based on information currently available and have been determined by the Company as reasonable.
• Considerable financial investments and long development time are required before a new drug is launched. The Company carefully develops new drugs by confirming their efficacy and safety. There is a possibility that their development may be discontinued before completion due to a variety of factors.
• "Products under Development" is based on the current development plans. The status may change depending on their progress.
• The information related to pharmaceuticals including those under development stated in this material are not intended to be advertisements or medical advice.

Copyright © KAKEN PHARMACEUTICAL CO., LTD. ALL Rights Reserved	2

Consolidated Statements of Income

		（amounts are rounded down to the nearest million yen）
	2Q of			YoY	Change	Plan
	2Q of
	FY2021	FY2022		Change	(%)	FY2022※
Net sales	37,588	36,819		▲768	98.0	76,400
Cost of sales	16,588	16,432		▲156	99.1	35,000
Selling, general and	11,963	12,178		214	101.8	26,400
administrative expenses
R&D expenses	4,008	4,330		321	108.0	10,400
Operating profit	9,036	8,209		▲826	90.8	15,000
Ordinary profit	9,290	8,555		▲734	92.1	15,500
Profit before income taxes	9,436	8,229		▲1,206	87.2	15,400
Profit	6,721	5,964		▲756	88.7	12,000
		（※ Plan for FY2022 was announced on May 11, 2022）

• Factors for the change in consolidated statements of income: drug price revisions and etc.
• Interim dividend of ¥75 per share
• Acquisition of treasury stock of 350 thousand shares

Copyright © KAKEN PHARMACEUTICAL CO., LTD. ALL Rights Reserved	3

Consolidated Net Sales by Segment

			(amounts are rounded down to the nearest million Yen)
	2Q of				YoY	Change
		2Q of
	FY2021		FY2022		Change	(%)
Domestic pharmaceuticals &	31,943		30,493		▲1,449	95.5
medical devices
Agrochemicals	1,651		1,906		255	115.4
Real estate business	1,192		1,219		27	102.3
Others (overseas pharmaceuticals,	2,801		3,199		397	114.2
bulk substances, etc.)
Total	37,588		36,819		▲768	98.0

Copyright © KAKEN PHARMACEUTICAL CO., LTD. ALL Rights Reserved	4

Consolidated Balance Sheets / Consolidated Statements of Cash Flows

Consolidated balance sheets	（amounts are rounded down to the nearest million yen）
	As of Mar.				YoY		Major change
		As of Sep.
	31, 2022		30, 2022		change		◆ Total assets:
Current assets	110,613		113,024		2,411		Cash and cash equivalents: ¥75,467 million
			(increase by ¥842 million)
Non-current assets	54,567		54,282		▲284
			◆ Total liabilities:
Total assets	165,181		167,307		2,126		Interest bearing debt: ¥3,850 million
			(no change)
							◆ Total net assets:
Current liabilities	19,049		19,234		184
Non-current liabilities	7,806		7,688		▲117		Retained earnings: ¥129,472 million
			(increase by ¥3,125 million)
Total liabilities	26,855		26,922		67		Treasury stocks: ▲¥30,025 million
							(increase by ¥1,331 million)
Total net assets	138,325		140,384		2,059		Non-controlling interest: ¥578 million

Consolidated statements of cash flows （amounts are rounded down to the nearest million yen）

	2Q of		2Q of		YoY
	FY2021		FY2022		change
Net cash provided by (used in)	5,434		6,427		993
operating activities
Net cash provided by (used in)	▲1,182		▲1,410		▲227
investing activities
Net cash provided by (used in)	▲5,287		▲4,174		1,112
financing activities
Cash and cash equivalents	76,270		75,467		▲802
at end of period

Major change

• Net cash provided by (used in) operating activities:
  Profit before income taxes: ¥8,229 million
• Net cash provided by (used in) investing activities:
  Purchase of tangible assets: ¥1,114 million
• Net cash provided by (used in) financing activities:
  Acquisition of treasury stocks: ¥1,339 million
  Cash dividend paid: ¥2,835 million

Copyright © KAKEN PHARMACEUTICAL CO., LTD. ALL Rights Reserved	5